| Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ... Genome Biology 17 (10), 2016 | 239 | 2016 |
| Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer N Lallous, K Dalal, A Cherkasov, PS Rennie International journal of molecular sciences 14 (6), 12496-12519, 2013 | 90 | 2013 |
| Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide … H Borgmann, N Lallous, D Ozistanbullu, E Beraldi, N Paul, K Dalal, L Fazli, ... European urology 73 (1), 4-8, 2018 | 89 | 2018 |
| Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer RSN Munuganti, MDH Hassona, E Leblanc, K Frewin, K Singh, D Ma, ... Chemistry & biology 21 (11), 1476-1485, 2014 | 82 | 2014 |
| Structure, functional characterization, and evolution of the dihydroorotase domain of human CAD A Grande-García, N Lallous, C Díaz-Tejada, S Ramón-Maiques Structure 22 (2), 185-198, 2014 | 77 | 2014 |
| Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models L Nappi, AH Aguda, N Al Nakouzi, B Lelj-Garolla, E Beraldi, N Lallous, ... The Journal of clinical investigation 130 (2), 699-714, 2020 | 60 | 2020 |
| Androgen receptor-binding sites are highly mutated in prostate cancer T Morova, DR McNeill, N Lallous, M Gönen, K Dalal, DM Wilson III, ... Nature communications 11 (1), 832, 2020 | 58 | 2020 |
| Androgen receptor plasticity and its implications for prostate cancer therapy O Snow, N Lallous, K Singh, N Lack, P Rennie, A Cherkasov Cancer treatment reviews 81, 101871, 2019 | 53 | 2019 |
| Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer LA Carabet, N Lallous, E Leblanc, F Ban, H Morin, S Lawn, F Ghaidi, ... European journal of medicinal chemistry 160, 108-119, 2018 | 51 | 2018 |
| An oncofetal glycosaminoglycan modification provides therapeutic access to cisplatin-resistant bladder cancer R Seiler, HZ Oo, D Tortora, TM Clausen, CK Wang, G Kumar, MA Pereira, ... European urology 72 (1), 142-150, 2017 | 51 | 2017 |
| The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers N Lallous, P Legrand, AG McEwen, S Ramón-Maiques, JP Samama, ... PloS one 6 (11), e27599, 2011 | 50 | 2011 |
| Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression F Zhang, M Biswas, S Massah, J Lee, S Lingadahalli, S Wong, C Wells, ... Nucleic Acids Research 51 (1), 99-116, 2023 | 46 | 2023 |
| Discovery of new catalytic topoisomerase II inhibitors for anticancer therapeutics VM Matias-Barrios, M Radaeva, Y Song, Z Alperstein, AR Lee, V Schmitt, ... Frontiers in oncology 10, 633142, 2021 | 39 | 2021 |
| Bypassing drug resistance mechanisms of prostate cancer with small molecules that target androgen Receptor–Chromatin interactions K Dalal, M Che, NS Que, A Sharma, R Yang, N Lallous, H Borgmann, ... Molecular cancer therapeutics 16 (10), 2281-2291, 2017 | 38 | 2017 |
| Computer-aided discovery of small molecules targeting the RNA splicing activity of hnRNP A1 in castration-resistant prostate cancer LA Carabet, E Leblanc, N Lallous, H Morin, F Ghaidi, J Lee, PS Rennie, ... Molecules 24 (4), 763, 2019 | 37 | 2019 |
| In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α K Singh, RSN Munuganti, E Leblanc, YL Lin, E Leung, N Lallous, M Butler, ... Breast Cancer Research 17, 1-17, 2015 | 31 | 2015 |
| Targeting binding function-3 of the androgen receptor blocks its co-chaperone interactions, nuclear translocation, and activation N Lallous, E Leblanc, RSN Munuganti, MDH Hassona, NA Nakouzi, ... Molecular cancer therapeutics 15 (12), 2936-2945, 2016 | 30 | 2016 |
| Development of an androgen receptor inhibitor targeting the N-Terminal domain of androgen receptor for treatment of castration resistant prostate cancer F Ban, E Leblanc, AD Cavga, CCF Huang, MR Flory, F Zhang, ... Cancers 13 (14), 3488, 2021 | 23 | 2021 |
| Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer AT Ton, K Singh, H Morin, F Ban, E Leblanc, J Lee, N Lallous, ... International journal of molecular sciences 21 (21), 8277, 2020 | 23 | 2020 |
| Evaluation of darolutamide (Odm201) efficiency on androgen receptor mutants reported to date in prostate cancer patients N Lallous, O Snow, C Sanchez, AK Parra Nuñez, B Sun, A Hussain, J Lee, ... Cancers 13 (12), 2939, 2021 | 21 | 2021 |
Artem CherkasovUniversity of British Columbia在 interchange.ubc.ca 的电子邮件经过验证
